Iqvia (NYSE:IQV) has been assigned a $97.00 target price by investment analysts at Mizuho in a note issued to investors on Wednesday. The firm presently has a “hold” rating on the medical research company’s stock. Mizuho’s target price points to a potential downside of 6.28% from the stock’s previous close.
IQV has been the topic of several other reports. KeyCorp reissued a “sector weight” rating and set a $100.00 price target on shares of Iqvia in a research note on Friday, November 10th. Credit Suisse Group reissued an “outperform” rating and set a $110.00 price target (up from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $107.00 price target on the stock in a research note on Wednesday, October 11th. TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Finally, SunTrust Banks reissued a “hold” rating and set a $114.00 price target on shares of Iqvia in a research note on Friday, November 3rd. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $107.97.
Shares of Iqvia (IQV) traded up $0.29 during trading on Wednesday, reaching $103.50. 714,353 shares of the company’s stock traded hands, compared to its average volume of 1,121,425. Iqvia has a twelve month low of $74.86 and a twelve month high of $110.67. The company has a market capitalization of $21,530.00, a price-to-earnings ratio of 356.90, a PEG ratio of 1.42 and a beta of 0.61. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29.
In related news, insider Ari Bousbib sold 46,080 shares of Iqvia stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $108.14, for a total value of $4,983,091.20. Following the transaction, the insider now directly owns 1,036,839 shares of the company’s stock, valued at $112,123,769.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total transaction of $999,700.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,806,558 shares of company stock worth $898,716,708. 6.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Street Advisors Inc. NC purchased a new position in shares of Iqvia in the fourth quarter worth $7,446,000. Nisa Investment Advisors LLC purchased a new position in shares of Iqvia in the fourth quarter worth $920,000. Bremer Trust National Association purchased a new position in shares of Iqvia in the fourth quarter worth $1,445,000. Westpac Banking Corp purchased a new position in Iqvia during the 4th quarter valued at $5,379,000. Finally, Sheets Smith Wealth Management purchased a new position in Iqvia during the 4th quarter valued at $5,770,000. 95.84% of the stock is currently owned by institutional investors.
About Iqvia
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
